Multiple Sclerosis Journal - Experimental, Translational and Clinical最新文献

{"title":"Low-intensity repetitive transcranial magnetic stimulation is safe and well tolerated by people living with MS - outcomes of the phase I randomised controlled trial (TAURUS).","authors":"Phuong Tram Nguyen, Amin Zarghami, Kalina Makowiecki, Natasha Stevens, Chigozie Ezegbe, Kain Kyle, Chenyu Wang, Linda Ly, Katie De La Rue, Mark R Hinder, Lewis Johnson, Jennifer Rodger, Samantha Cooper, Carlie L Cullen, Michael Barnett, Kaylene M Young, Bruce V Taylor","doi":"10.1177/20552173241252571","DOIUrl":"https://doi.org/10.1177/20552173241252571","url":null,"abstract":"<p><strong>Background: </strong>Low-intensity repetitive transcranial magnetic stimulation (rTMS), delivered as a daily intermittent theta burst stimulation (iTBS) for four consecutive weeks, increased the number of new oligodendrocytes in the adult mouse brain. Therefore, rTMS holds potential as a remyelinating intervention for people with multiple sclerosis (MS).</p><p><strong>Objective: </strong>Primarily to determine the safety and tolerability of our rTMS protocol in people with MS. Secondary objectives include feasibility, blinding and an exploration of changes in magnetic resonance imaging (MRI) metrics, patient-reported outcome measures (PROMs) and cognitive or motor performance.</p><p><strong>Methods: </strong>A randomised (2:1), placebo controlled, single blind, parallel group, phase 1 trial of 20 rTMS sessions (600 iTBS pulses per hemisphere; 25% maximum stimulator output), delivered over 4-5 weeks. Twenty participants were randomly assigned to 'sham' (<i>n</i> = 7) or active rTMS (<i>n</i> = 13), with the coil positioned at 90° or 0°, respectively.</p><p><strong>Results: </strong>Five adverse events (AEs) including one serious AE reported. None were related to treatment. Protocol compliance was high (85%) and blinding successful. Within participant MRI metrics, PROMs and cognitive or motor performance were unchanged over time.</p><p><strong>Conclusion: </strong>Twenty sessions of rTMS is safe and well tolerated in a small group of people with MS. The study protocol and procedures are feasible. Improvement of sham is warranted before further investigating safety and efficacy.</p>","PeriodicalId":18961,"journal":{"name":"Multiple Sclerosis Journal - Experimental, Translational and Clinical","volume":"10 2","pages":"20552173241252571"},"PeriodicalIF":2.8,"publicationDate":"2024-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11097717/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140958537","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical outcomes after use of checkpoint inhibitor immunotherapies in people with multiple sclerosis.","authors":"Alyssa N Nylander, William Rowles, Shane Poole, Riley Bove","doi":"10.1177/20552173241252563","DOIUrl":"10.1177/20552173241252563","url":null,"abstract":"<p><strong>Background: </strong>Immune checkpoint inhibitors (ICIs) represent a novel class of agents approved for the treatment of several cancers and progressive multifocal leukoencephalopathy (PML). However, due to the risk of autoimmune side effects, their use in people with autoimmune diseases such as multiple sclerosis (MS) has been limited.</p><p><strong>Objective: </strong>To characterize outcomes in a cohort of adults with MS who received ICIs.</p><p><strong>Methods: </strong>A single-center retrospective review of medical record data was performed for people with MS treated with ICIs.</p><p><strong>Results: </strong>Seven people with MS were identified, with a mean (SD) age at ICI use of 55.4 (13.7) years and a mean MS duration of 18.2 (12.2) years. Six were treated for cancer; 1 was treated for PML. After mean (SD) follow-up of 1.76 (2.15) years after ICI, outcomes are: no evidence of disease (2), residual metastatic disease (1), death due to cancer (1), death due to PML (1), and lost to follow-up (2). Notably, 0 out of 7 patients experienced an MS relapse; two out of six had new asymptomatic demyelinating magnetic resonance imaging lesions. In the three patients with expanded disability status scale (EDSS) scores at baseline and follow-up, EDSS remained stable (mean delta 0.13).</p><p><strong>Conclusion: </strong>In this cohort, no people with MS experienced clinical relapses and one-third experienced asymptomatic radiological activity following ICI treatment.</p>","PeriodicalId":18961,"journal":{"name":"Multiple Sclerosis Journal - Experimental, Translational and Clinical","volume":"10 2","pages":"20552173241252563"},"PeriodicalIF":2.8,"publicationDate":"2024-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11078085/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140892048","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The patient-reported wearing-off phenomenon with monoclonal antibody treatments for multiple sclerosis.","authors":"Lindsey M Marian, Kathleen A Harris, Devon S Conway","doi":"10.1177/20552173241251707","DOIUrl":"10.1177/20552173241251707","url":null,"abstract":"<p><strong>Background: </strong>Many patients report a wearing-off phenomenon with monoclonal antibody treatment for multiple sclerosis in which perceived benefits wear off before the next dose is due.</p><p><strong>Objectives: </strong>To determine prevalence of the wearing-off effect, symptoms experienced, impact on treatment satisfaction, and associated patient characteristics.</p><p><strong>Methods: </strong>Patients receiving natalizumab, ocrelizumab, ofatumumab, or rituximab at a tertiary multiple sclerosis center were invited to take an online survey interrogating their monoclonal antibody experience. Additional history and patient characteristic data were collected. Logistic regression was used to determine if patient characteristics predicted the wearing-off effect and linear regression to evaluate the impact of the wearing-off effect on treatment satisfaction. The models were adjusted for age, disease duration, race, sex, body mass index, education, and depression as measured by the Patient Health Questionnaire-9.</p><p><strong>Results: </strong>We received 258 qualifying responses and 141 (54.7%) patients reported the wearing-off phenomenon. The most common symptom was fatigue (47.7%). Higher Patient Health Questionnaire-9 scores were significantly associated with the wearing-off phenomenon (OR = 1.02, <i>p</i> = 0.005). The wearing-off effect (β = -0.52, <i>p</i> = 0.04) and higher Patient Health Questionnaire-9 (β = -0.09, <i>p</i> < 0.01) scores were associated with significantly reduced treatment satisfaction.</p><p><strong>Conclusion: </strong>The wearing-off phenomenon is common, associated with depression, and reduces treatment satisfaction. Research addressing mitigation strategies is needed.</p>","PeriodicalId":18961,"journal":{"name":"Multiple Sclerosis Journal - Experimental, Translational and Clinical","volume":"10 2","pages":"20552173241251707"},"PeriodicalIF":2.8,"publicationDate":"2024-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11075606/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140876867","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"High-resolution diffusion tensor imaging of the fornix predicts memory function in multiple sclerosis.","authors":"Katherine A Koenig, Ken E Sakaie, Daniel Ontaneda, Kedar R Mahajan, Se-Hong Oh, Kunio Nakamura, Stephen E Jones, Stephen M Rao, Mark J Lowe","doi":"10.1177/20552173241240937","DOIUrl":"10.1177/20552173241240937","url":null,"abstract":"<p><strong>Background: </strong>Cognitive dysfunction is a known symptom of multiple sclerosis (MS), with memory recognized as a frequently impacted domain. Here, we used high-resolution MRI at 7 tesla to build on cross-sectional work by evaluating the longitudinal relationship of diffusion tensor imaging (DTI) measures of the fornix to episodic memory performance.</p><p><strong>Methods: </strong>A sample of 80 people with multiple sclerosis (mean age 51.9 ± 8.1 years; 24% male) underwent baseline clinical evaluation, neuropsychological assessment, and MRI. Sixty-four participants had follow-up neuropsychological testing after 1-2 years. Linear regression was used to assess the relationship of baseline imaging measures to follow-up episodic memory performance, measured using the Selective Reminding Test and Brief Visuospatial Memory Test. A reduced prediction model included cognitive function at baseline, age, sex, and disease course.</p><p><strong>Results: </strong>Radial (β = -0.222, <i>p</i> < 0.026; likelihood ratio test (LRT) <i>p</i> < 0.018), axial (β = -0.270, <i>p</i> < 0.005; LRT <i>p</i> < 0.003), and mean (β = -0.242, <i>p</i> < 0.0139; LRT <i>p</i> < 0.009) diffusivity of the fornix significantly added to the model, with follow-up analysis indicating that a longer prediction interval may increase accuracy.</p><p><strong>Conclusion: </strong>These results suggest that fornix DTI has predictive value specific to memory function in MS and warrants additional investigation in the drive to develop predictors of disease progression.</p>","PeriodicalId":18961,"journal":{"name":"Multiple Sclerosis Journal - Experimental, Translational and Clinical","volume":"10 2","pages":"20552173241240937"},"PeriodicalIF":2.8,"publicationDate":"2024-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11075608/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140876866","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Coronavirus disease 2019 infection among working-aged people with multiple sclerosis and the impact of disease-modifying therapies.","authors":"Chantelle Murley, Emma Pettersson, Jan Hillert, Alejandra Machado, Emilie Friberg","doi":"10.1177/20552173241248293","DOIUrl":"https://doi.org/10.1177/20552173241248293","url":null,"abstract":"<p><strong>Background: </strong>The risk of coronavirus disease 2019 among people with multiple sclerosis with different disease-modifying therapies is not well established.</p><p><strong>Objective: </strong>To investigate the occurrence of coronavirus disease 2019 and the remaining symptoms among people with multiple sclerosis and the associations with different disease-modifying therapies.</p><p><strong>Methods: </strong>Individuals aged 20-50 listed in the Swedish Multiple Sclerosis Registry were invited to participate in a survey in 2021. Information on reported coronavirus disease 2019 infection and remaining symptoms were linked to individual-level register data. The risks by disease-modifying therapy of having coronavirus disease 2019 or having remaining symptoms were estimated with logistic regression.</p><p><strong>Results: </strong>Of the 4393 participants, 1030 (23.4%) self-reported coronavirus disease 2019 (749 confirmed and 281 suspected). The observed odds for coronavirus disease 2019 did not differ by disease-modifying therapy (<i>p</i>-values <0.05). The majority reporting coronavirus disease 2019 had fully recovered (68.5%), 4.2% were currently/recently sick, and 27.0% had symptoms remaining after 2 months. The most frequently reported remaining symptoms involved one's sense of smell or taste (37.0%), fatigue (20.0%), and breathing (12.0%). No statistically significant associations were observed between having remaining symptoms and the disease-modifying therapy.</p><p><strong>Conclusion: </strong>Despite the initial concerns of differing infection risks by MS treatments, we observed no differences in coronavirus disease 2019 occurrence or remaining symptoms among those who had coronavirus disease 2019. Nonetheless, exercising caution in interpreting our findings, it remains implicit that people with multiple sclerosis are particularly susceptible to infection and that lingering symptoms may persist beyond the initial infection.</p>","PeriodicalId":18961,"journal":{"name":"Multiple Sclerosis Journal - Experimental, Translational and Clinical","volume":"10 2","pages":"20552173241248293"},"PeriodicalIF":2.8,"publicationDate":"2024-04-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11055478/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140859816","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy of dalfampridine in neuromyelitis optica spectrum disorder: A pilot study.","authors":"Jérôme de Seze, Christine Clerc, Matthieu Béreau, Bertrand Bourre, Hélène Zephir, Nicolas Collongues, Laurent Kremer, Patrick Vermersch, Kevin Bigaut","doi":"10.1177/20552173241233952","DOIUrl":"10.1177/20552173241233952","url":null,"abstract":"<p><strong>Objective: </strong>To assess the efficacy of dalfampridine in patients with neuromyelitis optica spectrum disorder.</p><p><strong>Methods: </strong>We included 15 consecutive patients, who were started on a treatment of dalfampridine 10 mg twice daily for 2 weeks. Efficacy assessment was based on walking ability improvement using Timed-25-Foot Walk and 12-item Multiple Sclerosis Walking Scale tests.</p><p><strong>Results: </strong>The mean Timed-25-Foot Walk score was reduced from 14.8 (±2.4) to 11.3 (±1.9) seconds (<i>p</i> = 0.01). The mean score on the 12-item Multiple Sclerosis Walking Scale was reduced from 41.2 (±3.5) to 31.4 (±3.2) (<i>p</i> = 0.004).</p><p><strong>Conclusion: </strong>Dalfampridine seems to be useful for symptomatic treatment of walking impairment in neuromyelitis optica spectrum disorder.</p>","PeriodicalId":18961,"journal":{"name":"Multiple Sclerosis Journal - Experimental, Translational and Clinical","volume":"10 1","pages":"20552173241233952"},"PeriodicalIF":2.8,"publicationDate":"2024-02-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10908237/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140022217","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Frequency of cognitive impairment in patients with neuromyelitis optica spectrum disorder in Mexico.","authors":"Edgar R Valdivia-Tangarife, Fernando Cortés-Enríquez, Alejandra Morlett-Paredes, Teresita Villaseñor-Cabrera, Jorge I Gámez-Nava, Mario A Mireles-Ramírez, Laura González-López, Miguel Á Macías-Islas","doi":"10.1177/20552173241231678","DOIUrl":"10.1177/20552173241231678","url":null,"abstract":"<p><strong>Background: </strong>Between 29% and 67% of neuromyelitis optica spectrum disorder patients have cognitive alterations.</p><p><strong>Objective: </strong>To assess the frequency of cognitive impairment in patients with neuromyelitis optica spectrum disorder in Mexico using the Brief International Cognitive Assessment for Multiple Sclerosis.</p><p><strong>Methods: </strong>We evaluated 40 neuromyelitis optica spectrum disorder patients and 40 healthy controls from Mexico.</p><p><strong>Results: </strong>28 (70.0%) patients with neuromyelitis optica spectrum disorder had cognitive impairment in two or more cognitive domains. Student´s T test showed statistically poor performance by neuromyelitis optica spectrum disorder patients compared to healthy controls on all three neuropsychological test scores. This significant difference was observed on the Symbols Digit Modalities Test (<i>t</i> = 8.875; <i>p</i> ≤ 0.001); California Verbal Learning Test-II memory (<i>t</i> = 10.418; <i>p</i> ≤ 0.001); and Brief Visuospatial Memory Test Revised (<i>t</i> = 6.123; <i>p</i> ≤ 0.001).</p><p><strong>Conclusions: </strong>This study showed that 70% of neuromyelitis optica spectrum disorder patients exhibited cognitive impairment in two or more cognitive domains. Determining the frequency of cognitive impairment will guide the decision of Neuropsychologists in planning cognitive rehabilitation across various domains.</p>","PeriodicalId":18961,"journal":{"name":"Multiple Sclerosis Journal - Experimental, Translational and Clinical","volume":"10 1","pages":"20552173241231678"},"PeriodicalIF":2.8,"publicationDate":"2024-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10896058/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139975484","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Superficial white matter integrity in neuromyelitis optica spectrum disorder and multiple sclerosis.","authors":"Darko Komnenić, Owen Robert Phillips, Shantanu H Joshi, Claudia Chien, Tanja Schmitz-Hübsch, Susanna Asseyer, Friedemann Paul, Carsten Finke","doi":"10.1177/20552173231226107","DOIUrl":"10.1177/20552173231226107","url":null,"abstract":"<p><strong>Background: </strong>Superficial white matter (SWM) is a particularly vulnerable area of white matter adjacent to cerebral cortex that was shown to be a sensitive marker of disease severity in several neurological and psychiatric disorders, including multiple sclerosis (MS), but has not been studied in neuromyelitis optica spectrum disorder (NMOSD).</p><p><strong>Objective: </strong>To compare the integrity of SWM between MS patients, NMOSD patients and healthy controls, and explore the correlation of SWM integrity with cognitive performance and overall disability.</p><p><strong>Methods: </strong>Forty NMOSD patients, 48 MS patients and 52 healthy controls were included in the study. Mean diffusivity (MD) values obtained by diffusion tensor imaging were used as a measure of SWM integrity. Cognitive performance and overall disability were assessed with standardized tests.</p><p><strong>Results: </strong>Superficial white matter MD was increased in MS patients compared to healthy controls. Higher MD was associated with poorer spatial memory (most prominently in right temporal and right limbic lobe) and poorer information processing speed in MS patients. After adjusting for age, no significant differences of SWM MD were observed between NMOSD patients and healthy controls.</p><p><strong>Conclusion: </strong>Integrity of SWM is compromised in MS, but not in NMOSD, and can serve as a sensitive marker of disease severity.</p>","PeriodicalId":18961,"journal":{"name":"Multiple Sclerosis Journal - Experimental, Translational and Clinical","volume":"10 1","pages":"20552173231226107"},"PeriodicalIF":2.5,"publicationDate":"2024-01-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10807332/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139546682","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Onboarding of siponimod in secondary progressive multiple sclerosis patients in Australia: Novel, real-world evidence from the MSGo digital support programme.","authors":"T A Hardy, P Aouad, M H Barnett, S Blum, S Broadley, W M Carroll, D Crimmins, D Griffiths, S Hodgkinson, J Lechner-Scott, A Lee, R Malhotra, P McCombe, J Parratt, C Plummer, A Van der Walt, K Martel, R A Walker","doi":"10.1177/20552173231226106","DOIUrl":"10.1177/20552173231226106","url":null,"abstract":"<p><strong>Background: </strong>Siponimod is approved for use in people with secondary progressive multiple sclerosis (pwSPMS). An integrated digital platform, MSGo, was developed for pwSPMS and clinicians to help navigate the multiple steps of the pre-siponimod work-up.</p><p><strong>Objective: </strong>To explore real-world onboarding experiences of siponimod amongst pwSPMS in Australia.</p><p><strong>Methods: </strong>Retrospective, non-interventional, longitudinal, secondary analysis of data extracted from MSGo (20 April 2022). The primary endpoint was the average time for siponimod onboarding; secondary endpoints were adherence and sub-group analyses of variables influencing onboarding.</p><p><strong>Results: </strong>Mixed-cure modelling estimated that 58% of participants (<i>N</i> = 368, females 71%, median age of 59 years) registered in MSGo would ever initiate siponimod. The median time to initiation was 56 days (95% CI [47-59] days). Half of the participants cited 'waiting for vaccination' as the reason for initiation delay. Cox regression analyses found participants with a nominated care partner had faster onboarding (HR 2.1, 95% CI [1.5-3.0]) and were more likely to continue self-reporting daily siponimod dosing than were those without a care partner (HR 2.2, 95% CI [1.3-3.7]).</p><p><strong>Conclusions: </strong>Despite the limitations of self-reported data and the challenges of the COVID-19 pandemic, this study provides insights into siponimod onboarding in Australia and demonstrates the positive impact of care partner support.</p>","PeriodicalId":18961,"journal":{"name":"Multiple Sclerosis Journal - Experimental, Translational and Clinical","volume":"10 1","pages":"20552173231226106"},"PeriodicalIF":2.8,"publicationDate":"2024-01-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10787529/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139466734","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dairy and gluten in disease activity in multiple sclerosis.","authors":"Isabel A Temperley, Alexandra N Seldon, Madeline Aw Reckord, Claudia A Yarad, Farihah T Islam, Kerith Duncanson, Rodney A Lea, Jeannette Lechner-Scott, Vicki E Maltby","doi":"10.1177/20552173231218107","DOIUrl":"10.1177/20552173231218107","url":null,"abstract":"<p><strong>Background: </strong>Many diets promoted specifically for multiple sclerosis have been suggested to improve disease activity. Dairy and gluten are two components for which the recommendations vary between these diets. Existing research into the association between these dietary components and disease activity has been conflicting.</p><p><strong>Objective: </strong>To explore the relationship between dairy and gluten intake and disease activity in multiple sclerosis over a 2-year period, using no evidence of disease activity (NEDA) 3 status.</p><p><strong>Methods: </strong>186 participants' dairy and gluten intake was retrospectively estimated over 2 years using a dairy and gluten dietary screener. Estimated dairy and gluten intake was compared to disease activity, indicated by no evidence of disease activity 3 status, and quality of life, assessed by the Multiple Sclerosis International Quality of Life (MusiQoL) questionnaire.</p><p><strong>Results: </strong>No significant association was found between mean estimated dairy or gluten intake and NEDA 3 status (<i>p</i> = 0.15 and 0.60, respectively). Furthermore, there was no significant relationship between dairy or gluten intake and MusiQoL) scores (<i>p</i> = 0.11 and 0.51, respectively).</p><p><strong>Conclusion: </strong>Whilst we cannot rule out modest benefits due to our small sample size, we found that neither dairy nor gluten intake was associated with disease activity or quality of life in this study.</p>","PeriodicalId":18961,"journal":{"name":"Multiple Sclerosis Journal - Experimental, Translational and Clinical","volume":"9 4","pages":"20552173231218107"},"PeriodicalIF":2.8,"publicationDate":"2023-12-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10734333/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138830613","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}